Zacks Research Issues Negative Estimate for Avantor Earnings

Avantor, Inc. (NYSE:AVTR) – Analysts at Zacks Research dropped their Q2 2026 EPS estimates for shares of Avantor in a research report issued on Wednesday, February 5th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.28 per share for the quarter, down from their prior estimate of $0.29. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share.

Several other equities analysts have also commented on AVTR. UBS Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Wells Fargo & Company reduced their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday. Morgan Stanley reduced their target price on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday. Robert W. Baird reduced their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Finally, Royal Bank of Canada dropped their price target on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research report on Monday. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $26.15.

Avantor Price Performance

AVTR stock opened at $19.00 on Monday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor has a 52 week low of $18.49 and a 52 week high of $28.00. The firm’s fifty day moving average is $21.73 and its 200 day moving average is $23.47. The firm has a market cap of $12.93 billion, a P/E ratio of 41.30, a P/E/G ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period last year, the business posted $0.22 EPS.

Institutional Investors Weigh In On Avantor

Institutional investors and hedge funds have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB lifted its position in shares of Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after purchasing an additional 625 shares during the period. Smartleaf Asset Management LLC boosted its stake in Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after acquiring an additional 830 shares in the last quarter. UMB Bank n.a. bought a new stake in Avantor during the third quarter worth about $49,000. Global Retirement Partners LLC boosted its stake in Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after acquiring an additional 1,067 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.